Maxi Zumpe
Greifswald, MV 17475, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Affinity Affects the Functional Potency of Anti-GD2 Antibodies by Target-Mediated Drug Disposition.
Journal: Cancers
Published: June 04, 2025
Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study.
Journal: British journal of cancer
Published: May 05, 2023
A 3D Model of Human Buccal Mucosa for Compatibility Testing of Mouth Rinsing Solutions.
Journal: Pharmaceutics
Published: January 16, 2023
Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models.
Journal: Cancers
Published: January 03, 2023
BCL11B depletion induces the development of highly cytotoxic innate T cells out of IL-15 stimulated peripheral blood αβ CD8+ T cells.
Journal: Oncoimmunology
Published: December 12, 2022
Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments.
Journal: Cancers
Published: October 24, 2022
Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.
Journal: Frontiers in immunology
Published: April 02, 2021
Reduction of CD11b+ myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD2 antibody ch14.18/CHO.
Journal: Oncoimmunology
Published: November 05, 2020
Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy.
Journal: Frontiers in pediatrics
Published: July 13, 2020
Last Updated: 09/26/2026